Patient characteristics
| Characteristics (N = 16) . | Number of patients . |
|---|---|
| Sex, n (%) | |
| Men | 12 (75) |
| Women | 4 (25) |
| Age at cancer diagnosis, n (%) | |
| <60 y | 9 (56) |
| ≥60 y | 7 (44) |
| Hematologic | |
| CLL | 5 |
| AML | 3 |
| Mantle cell lymphoma | 3 |
| B-cell lymphoma NOS | 1 |
| ALL | 1 |
| Hodgkin lymphoma | 1 |
| Myeloma/plasmacytoma | 1 |
| Waldenstrom macroglobulinemia | 1 |
| Cancer-directed therapies, n (%) | |
| Conventional chemotherapy | 15 (94) |
| Stem cell transplant | 9 (56) |
| Total body irradiation | 2 (13) |
| Immunomodulating therapy | 13 (81) |
| Drugs used | |
| Rituximab | 9 |
| Alemtuzumab | 1 |
| Bortezomib | 2 |
| Brentuximab | 1 |
| Dasatinib | 1 |
| Idelalisib | 1 |
| Revlimid | 1 |
| Tositumomab | 1 |
| HuM195 | 1 |
| Interferon | 1 |
| IVIG | 2 |
| Vaccine therapy | 1 |
| No treatment | 1 |
| Rituximab | 9 |
| >6 mo of rituximab treatment | 8 |
| Characteristics (N = 16) . | Number of patients . |
|---|---|
| Sex, n (%) | |
| Men | 12 (75) |
| Women | 4 (25) |
| Age at cancer diagnosis, n (%) | |
| <60 y | 9 (56) |
| ≥60 y | 7 (44) |
| Hematologic | |
| CLL | 5 |
| AML | 3 |
| Mantle cell lymphoma | 3 |
| B-cell lymphoma NOS | 1 |
| ALL | 1 |
| Hodgkin lymphoma | 1 |
| Myeloma/plasmacytoma | 1 |
| Waldenstrom macroglobulinemia | 1 |
| Cancer-directed therapies, n (%) | |
| Conventional chemotherapy | 15 (94) |
| Stem cell transplant | 9 (56) |
| Total body irradiation | 2 (13) |
| Immunomodulating therapy | 13 (81) |
| Drugs used | |
| Rituximab | 9 |
| Alemtuzumab | 1 |
| Bortezomib | 2 |
| Brentuximab | 1 |
| Dasatinib | 1 |
| Idelalisib | 1 |
| Revlimid | 1 |
| Tositumomab | 1 |
| HuM195 | 1 |
| Interferon | 1 |
| IVIG | 2 |
| Vaccine therapy | 1 |
| No treatment | 1 |
| Rituximab | 9 |
| >6 mo of rituximab treatment | 8 |
ALL, acute lymphocytic leukemia; HuM195, humanized monoclonal antibody; IVIG, IV immunoglobulin; NOS, not otherwise specified.